Business Wire

Movado Partners With 5 New Global Ambassadors and Launches Icons Campaign

4.9.2024 15:00:00 CEST | Business Wire | Press release

Share

Movado, Swiss watchmaker since 1881, makes its next move and partners with legendary and emerging icons from Music, Sports, & Film

MOVADO (NYSE: MOV) is proud to announce its new roster of brand ambassadors starring in “When I Move You Move,” the brand’s new global campaign featuring legendary and emerging icons in acting, music, sports, and business. The campaign includes renowned actress and entrepreneur Jessica Alba, legendary Academy Award winning actress Julianne Moore, iconic Grammy Award winning rapper, actor and entrepreneur Ludacris, Pro Bowl and All-Pro running back Christian McCaffrey, and All-Star point guard and 2024 Team USA Summer Olympics team member and gold medalist, Tyrese Haliburton.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904383113/en/

Movado Launches Icons Campaign Featuring Ludacris, Christian McCaffrey, Jessica Alba, Tyrese Haliburton and Julianne Moore as Global Ambassadors. (Credit: Mert Alas & Marcus Piggott)

“We are proud of our multi-year partnership with this roster of amazing talent across culture and entertainment and to feature them in our 2024-2025 global brand campaign,” said Efraim Grinberg, Chairman and CEO, Movado Group. “It was important to us that we aligned with individuals that truly represent Movado’s legacy of innovation, commitment to excellence and iconic design. This campaign has an incredible amount of energy and movement that is dynamic and makes you feel connected to Movado.”

Movement was the inspiration for this campaign - as it’s the key component of the brand’s DNA, with Movado meaning “always in motion” in Esperanto, a language created in 1887 to break down communications barriers. The talent is captured moving to and interacting with Ludacris’ 2003 #1 Billboard and Grammy-nominated song “Stand Up.” The chorus “when I move you move” is a call to action for people to express their full potential by doing what truly moves them.

Movado partnered with Creative Director Robert Lussier from The Style Council and global fashion photographers Mert Alas & Marcus Piggott to come up with the vision. The styling was done by celebrity stylist Mel Ottenberg and choreographed by movement director Stephen Galloway.

“Over the last year, we’ve embarked on a journey to take our brand to new heights by developing a culturally relevant campaign that moves you - that literally makes you want to get up and move,” said Margot Grinberg, President, Movado. “Our goal is to be disruptive and stand out - do something unexpected that will make you stop and want to see more from Movado. It will keep our brand top of mind and engage new audiences globally.”

The “When I Move You Move” campaign features watches across key families, where each icon wears specific pieces that align with their unique and personal style.

The campaign will be featured throughout the year across television, digital and print media including magazines, out of home and across all social media platforms. To discover more about the campaign, go to Movado.com.

About MOVADO

Since 1881, Movado has always been in motion and always moving forward. Its commitment to modern design and innovation has made Movado one of the world’s premier watchmakers, with a proud 143-year heritage of Swiss craftsmanship, design and excellence. Expertly combining artistry, innovation and technology, Movado has earned over 100 patents and has timepieces on display in 20 museums worldwide.

The brand has been a long-time supporter of the performing arts and other worthy causes and is proud to partner with organizations such as Lincoln Center for the Performing Arts, Jazz at Lincoln Center, the Public Art Fund, The Studio Museum of Harlem, Derek Jeter’s Turn 2 Foundation, BCRF (Breast Cancer Research Foundation) and Jewelers for Children.

About Movado Group

Movado Group, Inc. designs, sources, and globally distributes and sells MOVADO®, MVMT®, OLIVIA BURTON®, EBEL®, CONCORD®, CALVIN KLEIN®, COACH®, TOMMY HILFIGER®, HUGO BOSS®, and LACOSTE® watches and, to a lesser extent jewelry and other accessories, and operates Movado Company Stores in the United States and Canada.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240904383113/en/

Contacts

For more information:

For more information:
Heather Cohen Sugarman
VP, Public Relations
Movado Group
hcohen@movadogroup.com

hcohen@movadogroup.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye